Trials / Completed
CompletedNCT01301833
Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes
Long-term Safety Study of MP-513 as Monotherapy or in Combination With Oral Antihyperglycaemic Agent in Japanese Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 462 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with oral antihyperglycaemic agent in patients with type 2 Diabetes for 52 weeks administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | teneligliptin | |
| DRUG | glinide | |
| DRUG | biguanide | |
| DRUG | alpha-glucosidase inhibitor |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2012-09-01
- Completion
- 2012-09-01
- First posted
- 2011-02-23
- Last updated
- 2026-01-02
- Results posted
- 2015-08-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01301833. Inclusion in this directory is not an endorsement.